Tae Jin Park, PharmD, MS

Senior Manager
AbbVie Inc.

Poster(s):

• (66) Analysis on the net costs of administering a prior authorization policy for onabotulinumtoxinA in the chronic migraine population
  Wednesday, October 29, 2025

• (355) Real-world switch rates of injectable migraine preventive therapies in patients with chronic migraine
  Wednesday, October 29, 2025